Applied Nutrition ups guidance as FY25 revenues rise 24%

Applied Nutrition has revealed that its revenues rose 24% to £107m for the year ended 31 July 2025.

This increase is expected to be ahead of market expectations and was driven by a strong second half performance of around £60m in revenue.

As a result of this, the company has stated it now expects its revenue for the financial year ending 31 July 2026 to be ahead of current market expectations at around £112.4m.

The board remains confident that the group’s core strengths, including its B2B-focused business model, breadth of high-quality products and industry leading new product development, will continue to drive sustained revenue growth and strong profitability over the long-term.

Alongside this, the company’s adjusted EBITDA was up approximately 19% year-on-year, from the £26m it posted in the previous year.

Its net cash, excluding IFRS 16 liabilities at the end of the period, is also expected to be ahead of market expectations at approximately £18.5m.

Thomas Ryder, CEO of Applied Nutrition, said: “We are proud to report that we have exceeded the guidance we gave at our IPO, with our first full-year results expected to come in ahead of market expectations. Our focus and ambition remain as strong as ever – in delivering for our shareholders, customers and team – and we are excited about the opportunities we have in the pipeline for the year ahead.”

Headquartered in the UK, Applied Nutrition sells products in over 85 countries worldwide and has a diverse product range, targeting elite athletes, gym goers and health-conscious consumers.

The company largely operates a global business-to-business model, which has facilitated a low risk, highly cost-effective go-to-market strategy.